非酒精性脂肪性肝病并发门静脉血栓的研究进展

龚航; 李良平

doi:10.3969/j.issn.1001-5256.2020.09.045

非酒精性脂肪性肝病并发门静脉血栓的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.09.045

龚航,
李良平

1. 自贡市第一人民医院消化内科
2. 四川省医学科学院·四川省人民医院消化内科

详细信息

中图分类号: R575
计量
- 文章访问数: 542
- HTML全文浏览量: 18
- PDF下载量: 89
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Research advances of portal vein thrombosis in nonalcoholic fatty liver disease

Department of Gastroenterology, The First People’s Hospital of Zigong

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)作为我国第一大慢性肝病,其肝外疾病[包括心血管疾病、门静脉血栓(PVT)等]的发病率和病死率不断增加。NAFLD并发PVT的机制与传统肝硬化有明显区别。从三级凝血障碍角度入手,从三个不同等级且阶梯式地阐述了NAFLD并发PVT的发病机制,描述了运动预防和治疗NAFLD发生PVT的全新观念,为NAFLD并发PVT的肝移植受者提出了技术挑战,对提高患者预后和生存质量有重要的意义。
- 非酒精性脂肪性肝病 /
- 静脉血栓形成 /
- 肝移植
Abstract: Nonalcoholic fatty liver disease( NAFLD) is the most important chronic liver disease in China,with increasing morbidity and mortality rates of extrahepatic diseases such as cardiovascular diseases and portal vein thrombosis( PVT). NAFLD complicated by PVT has a different mechanism from liver cirrhosis. Starting from grade Ⅲ coagulation disorder,this article elaborates on the pathogenesis of NAFLD complicated by PVT from three different grades and in steps and describes the new concept of sports and exercise in the prevention and treatment of NAFLD complicated by PVT,which brings a technical challenge for liver transplantation recipients with NAFLD complicated by PVT and is of great significance to improve the prognosis and quality of life of patients.
- non-alcoholic fatty liver disease /
- venous thrombosis /
- liver transplantation

HTML全文

参考文献(38)

[1] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[2] CHARLTON MR,BURNS JM,PEDERSEN RA,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the united states[J]. Gastroenterology,2011,141(4):1249-1253.

[3] STINE JG,SHAH NL,ARGO CK,et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis[J]. Liver Transpl,2015,21(8):1016-1021.

[4] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.

[5] FAN JG,KIM SU,WONG VW. New trends on obesity and nafld in asia[J]. J Hepatol,2017,67(4):862-873.

[6] LI SP,WANG QC. Progress of the epidemiology of non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol,2017,26(10):1085-1087.(in Chinese)李生鹏，王全楚．非酒精性脂肪性肝病的流行病学进展[J]．胃肠病学和肝病学杂志，2017,26(10):1085-1087.

[7] KHASPEKOVA SG,ZIURIAEV IT,IAKUSHKIN VV,et al. Mean platelet volume:Interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels[J]. Biomed Khim,2014,60(1):94-108.

[8] BASARANOGLU M,NAJJAR SM,DEMIRBAG AE,et al. Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list[J]. World J Hepatol,2016,8(7):376-384.

[9] STEINBERG HO,BARON AD. Insulin-mediated vasodilation:Why one’s physiology could be the other’s pharmacology[J]. Diabetologia,1999,42(4):493-495.

[10] VERRIJKEN A,FRANCQUE S,MERTENS I,et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2014,59(1):121-129.

[11] LOMBARDI AM,FABRIS R,BERTI DE MARINIS G,et al. Defective adamts13 synthesis as a possible consequence of nash in an obese patient with recurrent thrombotic thrombocytopenic purpura[J]. Eur J Haematol,2014,92(6):497-501.

[12] TRIPODI A,FRACANZANI AL,PRIMIGNANI M,et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease[J]. J Hepatol,2014,61(1):148-154.

[13] KOTRONEN A,JOUTSI-KORHONEN L,SEVASTIANOVA K,et al. Increased coagulation factor VIII,IX,XI and XII activities in non-alcoholic fatty liver disease[J]. Liver Int,2011,31(2):176-183.

[14] CIGOLINI M,TARGHER G,AGOSTINO G,et al. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men-role of the metabolic syndrome[J]. Thromb Haemost,1996,76(1):69-73.

[15] TRIPODI A. Thrombin generation assay and its application in the clinical laboratory[J]. Clin Chem,2016,62(5):699-707.

[16] NORTHUP PG,ARGO CK,SHAH N,et al. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease:Mechanisms,human evidence,therapeutic implications,and preventive implications[J]. Semin Liver Dis,2012,32(1):39-48.

[17] BALTA G,ALTAY C,GURGEY A. Pai-1 gene 4g/5g genotype:A risk factor for thrombosis in vessels of internal organs[J]. Am J Hematol,2002,71(2):89-93.

[18] STINE JG,NORTHUP PG. Coagulopathy before and after liver transplantation:From the hepatic to the systemic circulatory systems[J]. Clin Liver Dis,2017,21(2):253-274.

[19] KILLEWICH LA,MACKO RF,MONTGOMERY PS,et al. Exercise training enhances endogenous fibrinolysis in peripheral arterial disease[J]. J Vasc Surg,2004,40(4):741-745.

[20] EL-SAYED MS,EL-SAYED ALI Z,AHMADIZAD S. Exercise and training effects on blood haemostasis in health and disease:An update[J]. Sports Med,2004,34(3):181-200.

[21] FRANCIS RM,ROMEYN CL,COUGHLIN AM,et al. Age and aerobic training status effects on plasma and skeletal muscle tpa and PAI-1[J]. Eur J Appl Physiol,2014,114(6):1229-1238.

[22] KUPCHAK BR,CREIGHTON BC,ARISTIZABAL JC,et al.Beneficial effects of habitual resistance exercise training on coagulation and fibrinolytic responses[J]. Thromb Res,2013,131(6):e227-e234.

[23] POLLOCK ML,FRANKLIN BA,BALADY GJ,et al. AHA science advisory. Resistance exercise in individuals with and without cardiovascular disease:Benefits, rationale, safety,and prescription:An advisory from the committee on exercise,rehabilitation,and prevention,council on clinical cardiology,american heart association; position paper endorsed by the american college of sports medicine[J]. Circulation,2000,101(7):828-833.

[24] SKURK T,HAUNER H. Obesity and impaired fibrinolysis:Role of adipose production of plasminogen activator inhibitor-1[J]. Int J Obes Relat Metab Disord,2004,28(11):1357-1364.

[25] CUI SB,SHU RH,YAN SP,et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Eur J Gastroenterol Hepatol,2015,27(8):914-919.

[26] CHEN H,LIU L,QI X,et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol,2016,28(1):82-89.

[27] QI X,HAN G,FAN D. Management of portal vein thrombosis in liver cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2014,11(7):435-446.

[28] QUILLIN RC 3rd,WILSON GC,SUTTON JM,et al. Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation[J]. Surgery,2014,156(4):1049-1056.

[29] PONZIANI FR,ZOCCO MA,SENZOLO M,et al. Portal vein thrombosis and liver transplantation:Implications for waiting list period,surgical approach,early and late follow-up[J].Transplant Rev(Orlando),2014,28(2):92-101.

[30] TARANTINO G,CITRO V,ESPOSITO P,et al. Blood ammonia levels in liver cirrhosis:A clue for the presence of portosystemic collateral veins[J]. BMC Gastroenterol,2009,9:21.

[31] ENGLESBE MJ,KUBUS J,MUHAMMAD W,et al. Portal vein thrombosis and survival in patients with cirrhosis[J]. Liver Transpl,2010,16(1):83-90.

[32] AYALA R,GRANDE S,BUSTELOS R,et al. Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients[J]. BMC Gastroenterol,2012,12:114.

[33] GHABRIL M,AGARWAL S,LACERDA M,et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation:Analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients[J]. Transplantation,2016,100(1):126-133.

[34] SUAREZ ARTACHO G,BARRERA PULIDO L,ALAMO MARTINEZ JM,et al. Outcomes of liver transplantation in candidates with portal vein thrombosis[J]. Transplant Proc,2010,42(8):3156-3158.

[35] KARVELLAS CJ,CARDOSO FS,SENZOLO M,et al. Clinical impact of portal vein thrombosis prior to liver transplantation:A retrospective cohort study[J]. Ann Hepatol,2017,16(2):236-436.

[36] BERTELLI R,NARDO B,MONTALTI R,et al. Liver transplantation in recipients with portal vein thrombosis:Experience of a single transplant center[J]. Transplant Proc,2005,37(2):1119-1121.

[37] PAN C,SHI Y,ZHANG JJ,et al. Single-center experience of253 portal vein thrombosis patients undergoing liver transplantation in China[J]. Transplant Proc,2009,41(9):3761-3765.

[38] AGBIM U,JIANG Y,KEDIA SK,et al. Impact of nonmalignant portal vein thrombosis in transplant recipients with nonalcoholic steatohepatitis[J]. Liver Transpl,2019,25(1):68-78.

施引文献

资源附件(0)

访问统计